Impact of Infections on Long-Term Results after Heart Transplantation

Introduction

One of the primary goals in follow-up of patients after heart transplantation (HTX) is the prevention and effective treatment of infection, one of the most common life-threatening complications of long-term immunosuppressive therapy [1]. After solid organ transplantation, a typical pattern of infection can be observed due to comparable immunosuppressive regimens [1]. This helps developing a differential diagnosis and establishing effective preventive strategies in transplant recipients who present with infectious diseases.

References

• 1 Fishman J A. Infection in solid-organ transplant recipients.  N Engl J Med. 2007;  357 2601-2614
• 2 Preiksaitis J K, Sandhu J, Strautman M. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non-WBC-reduced blood components not screened for CMV antibody (1984 to 1996): experience at a single Canadian center.  Transfusion. 2002;  42 396-402
• 3 Dengler T J, Raftery M J, Werle M, Zimmermann R, Schonrich G. Cytomegalovirus infection of vascular cells induces expression of pro-inflammatory adhesion molecules by paracrine action of secreted interleukin-1beta.  Transplantation. 2000;  69 1160-1168
• 4 Kalil A C, Levitsky J, Lyden E, Stoner J, Freifeld A G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.  Ann Intern Med. 2005;  143 870-880
• 5 Snydman D R. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis.  Clin Infect Dis. 2005;  40 709-712
• 6 Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.  Am J Transplant. 2008;  8 975-983
• 7 Martin D F, Sierra-Madero J, Walmsley S, Wolitz R A, Macey K, Georgiou P. et al . A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.  N Engl J Med. 2002;  346 1119-1126
• 8 Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report.  Am J Transplant. 2004;  4 222-230
• 9 Maurmann S, Fricke L, Wagner H J, Schlenke P, Hennig H, Steinhoff J. et al . Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers.  J Clin Microbiol. 2003;  41 5419-5428
• 10 Benden C, Aurora P, Burch M, Cubitt D, Lloyd C, Whitmore P. et al . Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction.  J Heart Lung Transplant. 2005;  24 2103-2108
• 11 Doesch A O, Konstandin M, Celik S, Kristen A, Frankenstein L, Sack F U. et al . Epstein-Barr virus load in whole blood is associated with immunosuppression, but not with post-transplant lymphoproliferative disease in stable adult heart transplant patients.  Transpl Int. 2008;  21 (10) 963-971
• 12 Arora S, Jenum P A, Aukrust P, Rollag H, Andreassen A K, Simonsen S. et al . Pre-transplant toxoplasma gondii seropositivity among heart transplant recipients is associated with an increased risk of all-cause and cardiac mortality.  J Am Coll Cardiol. 2007;  50 1967-1972